Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accounts Payables (2016 - 2025)

Catalyst Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $11.2 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 32.49% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $11.2 million, down 32.49%, while the annual FY2025 figure was $11.2 million, 32.49% down from the prior year.
  • Accounts Payables reached $11.2 million in Q4 2025 per CPRX's latest filing, up from $9.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $16.6 million in Q4 2024 to a low of $2.3 million in Q2 2022.
  • Average Accounts Payables over 5 years is $6.7 million, with a median of $4.9 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: tumbled 49.63% in 2021, then skyrocketed 272.2% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $2.8 million in 2021, then surged by 43.61% to $4.0 million in 2022, then surged by 272.2% to $14.8 million in 2023, then grew by 12.15% to $16.6 million in 2024, then tumbled by 32.49% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Accounts Payables are $11.2 million (Q4 2025), $9.1 million (Q3 2025), and $5.5 million (Q2 2025).